Celyad Oncology SA (CYAD.BR)
EUR 0.55
(19.87%)
EUR 0.55
(19.87%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 33 Thousand EUR | 102.29% |
| 2022 | -1.44 Million EUR | 5.26% |
| 2021 | -1.52 Million EUR | -30500.0% |
| 2020 | 5000.00 EUR | -16.67% |
| 2019 | 6000.00 EUR | -99.81% |
| 2018 | 3.11 Million EUR | 2.98% |
| 2017 | 3.02 Million EUR | -64.29% |
| 2016 | 8.47 Million EUR | 232.78% |
| 2015 | -6.37 Million EUR | -20677.42% |
| 2014 | 31 Thousand EUR | 101.28% |
| 2013 | -2.41 Million EUR | 63.57% |
| 2012 | -6.62 Million EUR | -14.87% |
| 2011 | -5.77 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 5000.00 EUR | 0.0% |
| 2023 FY | 889 Thousand EUR | 161.74% |
| 2023 Q4 | 33 Thousand EUR | 0.0% |
| 2023 Q2 | -397 Thousand EUR | 0.0% |
| 2022 FY | -1.44 Million EUR | 5.26% |
| 2022 Q4 | -469 Thousand EUR | 0.0% |
| 2022 Q2 | -971 Thousand EUR | 0.0% |
| 2022 Q1 | - EUR | 100.0% |
| 2021 Q2 | -841 Thousand EUR | 0.0% |
| 2021 Q4 | -679 Thousand EUR | 0.0% |
| 2021 FY | -1.52 Million EUR | -30500.0% |
| 2021 Q1 | - EUR | 100.0% |
| 2021 Q3 | - EUR | 100.0% |
| 2020 FY | 5000.00 EUR | -16.67% |
| 2020 Q3 | - EUR | -100.0% |
| 2020 Q4 | -937 Thousand EUR | 0.0% |
| 2020 Q2 | 5000.00 EUR | 0.0% |
| 2019 Q2 | -894.5 Thousand EUR | -59733.33% |
| 2019 FY | 6000.00 EUR | -99.81% |
| 2019 Q4 | 6000.00 EUR | 0.0% |
| 2019 Q1 | 1500.00 EUR | -99.75% |
| 2018 Q2 | 2.51 Million EUR | 223.34% |
| 2018 Q1 | 778.75 Thousand EUR | 3144.79% |
| 2018 FY | 3.11 Million EUR | 2.98% |
| 2018 Q4 | 597 Thousand EUR | 0.0% |
| 2017 Q2 | 2.97 Million EUR | 293.92% |
| 2017 FY | 3.02 Million EUR | -64.29% |
| 2017 Q4 | 24 Thousand EUR | 0.0% |
| 2017 Q1 | 756.25 Thousand EUR | -91.06% |
| 2016 Q4 | 8.45 Million EUR | 0.0% |
| 2016 FY | 8.47 Million EUR | 232.78% |
| 2016 Q2 | 14 Thousand EUR | -99.34% |
| 2016 Q1 | 2.11 Million EUR | 105775.0% |
| 2015 Q4 | 2000.00 EUR | 300.0% |
| 2015 FY | -6.37 Million EUR | -20677.42% |
| 2015 Q3 | 500.00 EUR | 0.0% |
| 2015 Q2 | 500.00 EUR | 0.0% |
| 2015 Q1 | 500.00 EUR | -98.39% |
| 2014 Q1 | 7750.00 EUR | 100.25% |
| 2014 FY | 31 Thousand EUR | 101.28% |
| 2014 Q4 | 31 Thousand EUR | 300.0% |
| 2014 Q3 | 7750.00 EUR | 0.0% |
| 2014 Q2 | 7750.00 EUR | 0.0% |
| 2013 Q3 | -603.8 Thousand EUR | 81.08% |
| 2013 Q4 | -3.15 Million EUR | -422.55% |
| 2013 FY | -2.41 Million EUR | 63.57% |
| 2013 Q1 | -603.8 Thousand EUR | -0.0% |
| 2013 Q2 | -3.19 Million EUR | -428.6% |
| 2012 Q2 | -1.65 Million EUR | 0.0% |
| 2012 FY | -6.62 Million EUR | -14.87% |
| 2012 Q1 | -1.65 Million EUR | -0.0% |
| 2012 Q3 | -1.65 Million EUR | -0.0% |
| 2012 Q4 | -603.8 Thousand EUR | 63.57% |
| 2011 Q4 | -1.65 Million EUR | -14.87% |
| 2011 Q1 | -1.44 Million EUR | -0.0% |
| 2011 Q2 | -1.44 Million EUR | 0.0% |
| 2011 Q3 | -1.44 Million EUR | -0.0% |
| 2011 FY | -5.77 Million EUR | 0.0% |
| 2010 Q4 | -1.44 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | 94.66% |
| ABIVAX Société Anonyme | 3.91 Million EUR | 99.157% |
| Adocia SA | 1.38 Million EUR | 97.617% |
| Aelis Farma SA | 12.35 Million EUR | 99.733% |
| Biophytis S.A. | -803 Thousand EUR | 104.11% |
| Advicenne S.A. | 1.42 Million EUR | 97.686% |
| genOway Société anonyme | 20.1 Million EUR | 99.836% |
| IntegraGen SA | 5.01 Million EUR | 99.342% |
| Medesis Pharma S.A. | -2.66 Million EUR | 101.238% |
| Neovacs S.A. | 29.31 Thousand EUR | -12.574% |
| NFL Biosciences SA | -56.06 Thousand EUR | 158.861% |
| Plant Advanced Technologies SA | 2.15 Million EUR | 98.467% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 102.325% |
| Sensorion SA | 3.78 Million EUR | 99.129% |
| Theranexus Société Anonyme | -4.63 Million EUR | 100.711% |
| TME Pharma N.V. | -127 Thousand EUR | 125.984% |
| Valbiotis SA | 2.66 Million EUR | 98.763% |
| TheraVet SA | -530.79 Thousand EUR | 106.217% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | 97.395% |
| argenx SE | 925.49 Million EUR | 99.996% |
| BioSenic S.A. | 543 Thousand EUR | 93.923% |
| DBV Technologies S.A. | 4.15 Million EUR | 99.207% |
| Galapagos NV | 203.73 Million EUR | 99.984% |
| Genfit S.A. | 28.22 Million EUR | 99.883% |
| GeNeuro SA | -293.8 Thousand EUR | 111.232% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | 98.345% |
| Innate Pharma S.A. | -4.12 Million EUR | 100.801% |
| Inventiva S.A. | 17.5 Million EUR | 99.811% |
| MaaT Pharma SA | 1.65 Million EUR | 98.006% |
| MedinCell S.A. | 9.28 Million EUR | 99.645% |
| Nanobiotix S.A. | 36.2 Million EUR | 99.909% |
| Onward Medical N.V. | -14.81 Million EUR | 100.223% |
| Oryzon Genomics S.A. | 13.94 Million EUR | 99.763% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 98.518% |
| Oxurion NV | 104 Thousand EUR | 68.269% |
| Pharming Group N.V. | 220.1 Million EUR | 99.985% |
| Poxel S.A. | 1000.00 EUR | -3200.0% |
| GenSight Biologics S.A. | 3 Million EUR | 98.9% |
| Transgene SA | -28.4 Million EUR | 100.116% |
| Financière de Tubize SA | -2.02 Million EUR | 101.626% |
| UCB SA | 3.34 Billion EUR | 99.999% |
| Valneva SE | 52.83 Million EUR | 99.938% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 101.066% |